A series of substituted 2,7-dimethylimidazo[1,2-a]pyridine-3-carboxamides derivatives 5a-5m were synthesized through multi-step reactions. To achieve the synthesis of the desired compounds monobromo and dibromo substituted 2-amino-γ-picoline was reacted with ethyl 2-chloroacetoacetate. The crude ethyl ester subjected to hydrolysis in presence of lithium hydroxide to get 2a and 2b, with imidazo[1,2-a]pyridine-3-carboxylic acid to get 3a-3b, on treatment with substituted amines 4a-4g to get desired product 5a-5m in presence of EDCI and HOBt. The substituted imidazo[1,2-a]pyridine-3-carboxamides are characterized by FTIR, 1 H-NMR,
tested for various biological activities such as antiulcer [1] , antibacterial [2] , antimicrobial [3] , antifungal [4] , and antiviral [5] [6] agents. Various imidazo fused heterocycles with aryloxy alkylamines side chain including imidazo[1,2-a]pyridines act as calcium channel blockers or as local anaesthetics [7] . Byth and co-workers [8] have synthesized various pyrimidine sulfonamide substituted imidazo[1,2-a]pyridine as cyclindependent kinase (CDK) inhibitors which led to the identification of potent and selective inhibitors of CDK2 and CDK1. Several 8-arylimidazo[1,2-a]pyridines have been synthesized and evaluated as cardiotonic agents [9] . Some highly substituted imidazo[1,2-a]pyridines have been substituted as gastric antisecretory agents useful as gastric antiulcer agents [10] . Zhonghui Lu, Gregory R. Ott. and co-worker [11] [12] have synthesized a series of 2,3-substituted imidazo[1,2-a]pyridine derivatives which resemble (3S, 4S)pyrrolidine-N-hydroxy-3-carboxamide and (3R, 4R)pyran-N-hydroxy-3-carboxamide has been reported to have potent selectivity against tumor necrosis factor converting enzyme (TACE). The synthesis and tuberculosis activity of various substituted imidazo[1,2-a]pyridine-3-carboxamides have been reported [13] . Katherine A.
Abrahams et al. [14] described the synthesis and biological activity of imidazo [1,2-a] pyridine-3-carboxamides against Mycobacterium tuberculosis. Garrett C. Moraski et al.
synthesized a series of nine 2,7-dimethylimidazo[1,2-a]pyridine-3-car-boxamides and one 2,6-dime-thylimidazo[1,2-a]pyrimidine-3-carboxamide and evaluated for their in vitro antituberculosis activity against replicating, nonreplicating, multi-and extensive drug resistant Mtb strains [15] . Linhu Li et al. [16] have developed the synthesis and antituberculosis activity of various imidazo[1,2-a]pyridine-3-car-boxamide hybrids with extended amine functionality. Recently Samala G. et al. [17] 
Materials and Methods
Melting points of compounds were determined in open capillary tubes in silicon oil bath using a Veego melting point apparatus and are uncorrected. . Thin layer chromatography (TLC) was performed on silica F254 coated aluminum plates (Merck) as adsorbent and the spots were visualized using ultraviolet light or iodine chamber.
Chemistry
We synthesized imidazo[1,2-a]pyridine-3-carboxamide derivatives and evaluated them for Antituberculosis Activity. Figure 1 envisages the schematic representation for the synthesis of (un)substituted 2,7-dimethylimidazo[1,2-a]pyridine-3-carboxamides (5a-5m). For the synthesis of the desired molecules, mono bromo and dibromo substituted 2-amino-γ-picoline (1a-1b) were reacted with ethyl 2-chloroacetoacetate in presence of base to give ethyl imidazo[1,2-a]pyridine-3-carboxylates (2a-2b). These esters were then hydrolized to give imidazo[1,2-a]pyridine-3-carboxylic acids (3a-3b). These acid derivatives were treated with (un)substituted anilines (4a-4f) using hydroxybenzotriazole (HOBt) and EDCI as coupling agent to afford (un)substituted 2,7-di-methylimidazo[1,2-a]pyridine-3-carboxamides (5a-5m).
The FT-IR spectrum of hydrazone 5a, as a representative example, showed strong absorption bands at 1654 and 1595 cm −1 due to amide, C=O stretching and N-H bending respectively. The broad peak at 3138 cm −1 is attributed to amide N-H stretching. Its 1 H-NMR spectrum revealed, in addition to expected aromatic signals, three singlets at δ 2.69, 2.87, 9.67 ppm are assignable to the two methyl groups and amide proton (-NH-C=O), respectively. In addition, the 13 C-NMR spectrum of 5a displayed characteristic peak at δ 158.5 ppm assignable to carbonyl carbon of amide. Moreover the EIMS spectrum of 5a revealed molecular ion peak at m/z 423.9 (M+) corresponding to mole-
In a similar manner, compounds 5b-5m were prepared and characterized as shown in Table 1 and Table 2 .
Experiment

Preparation of Ethyl 6-Bromo-2,7-Dimethylimidazo[1,2-a] Pyridine-3-Carboxylate (2a)
A mixture of 5-bromo-4-methylpyridin-2-amine (10.0 g, 53.5 mmol) and ethyl 2-chloroacetoacetate (8.13 ml, 58.8 mmol) were taken in 1,2-dimethoxyethane (107 mL) and heated to reflux for 16 hours. The reaction mixture was concentrated under reduced pressure to get crude compound. Table 2 . Structures of compounds 5h-5m.
The crude compound was then purified by column chromatography using 15% ethylacetate (EtOAc) in hexane as eluent to get ethyl 6-bromo-2,7-dimethylimidazo- 
Preparation of Ethyl 6,8-Dibromo-2,7-Dimethylimidazo[1,2-a] Pyridine-3-Carboxylate (2b)
Compound (2b) prepared by similar process 4.1. (11.47 g, 57%) as an off-white solid.
Preparation of 6-Bromo-2,7-Dimethylimidazo[1,2-a] Pyridine-3-Carboxylic Acid (3a)
A mixture of 6-bromo-2,7-dimethylimidazo[1,2-a]pyridine-3-carboxylate (9.000 g, 30.3 mmol) and Lithium hydroxide (1.088 g, 45.4 mmol) were taken in THF/Water (1:1) (60 mL) and stirred at room temperature for 14 h. The reaction mixture extracted three times with 25 ml of ethyl acetate, further organic layers were discarded. Aqueous layer acidified with 2 NHCl at 5˚C -10˚C till the reaction mixture turned to pH ~5, the precipitate formed was filtered and dried to get 6-bromo-2, To the stirred solution of carboxylic acid (3a-3b) (1.0 equiv), EDCI (1.2 equiv), HOBt (1.2 equiv) and Et 3 N (2.5 equiv) in DMF at 0˚C, was added compound (4a-4g) (1.05 equiv) and allowed to stir at room temperature for 22 h. The reaction mixture was diluted with dichloromethane, washed with water and the separated organic layer was concentrated under reduced pressure. The crude compound was further purified by column chromatography using 30% EtOAc/Hexanes as the eluent. The reaction mixture was stirred for 30 min and then aniline 4a (0.138 ml, 1.509 mmol) was added. The reaction mixture was allowed to stir further at room temperature for 22 h. The reaction mixture was then diluted with dichloromethane and washed with water and the separated organic layer was concentrated under reduced pressure, purified by column chromatography using 30% EtOAc/Hexanes as eluent to get title compound in 70% yield (0.42 g) White solid; m.p. = 134˚C -137˚C; 1 
Results and Discussion
Antimycobacterial activity
The anti-tubercular activity of the synthesized compounds (5a-5m) against Mycobacterium tuberculosis ( 
Conclusion
In conclusion, new derivatives of imidazo[1,2-a]pyridine have been synthesized successfully with good yield. The experimental data for the evaluation of anti-tuberculosis activity revealed that most of the synthesized compounds 5a-5m demonstrated Figure 2 . MIC in µg/mL for test samples 5a-5m.
moderate to good antituberculosis activity. Among the tested compounds 5b, 5d and 5e were found to be the most active with minimum inhibitory concentration (MIC) of 12.5 μg/mL against Mycobacterium tuberculosis (H37 RV strain) ATCC No-27294 with minimum inhibitory concentration of 12.5 μg/ml. This study would pave the way for future development of more effective imidazo[1,2-a]pyridine analogs for applications in biological science.
